Refining the approach to vaccines against influenza A viruses with pandemic potential
Identifieur interne : 000815 ( Pmc/Curation ); précédent : 000814; suivant : 000816Refining the approach to vaccines against influenza A viruses with pandemic potential
Auteurs : Rita Czako [États-Unis] ; Kanta Subbarao [États-Unis]Source :
- Future virology [ 1746-0794 ] ; 2015.
Abstract
Vaccination is the most effective strategy for prevention and control of influenza. Timely production and deployment of seasonal influenza vaccines is based on an understanding of the epidemiology of influenza and on global disease and virologic surveillance. Experience with seasonal influenza vaccines guided the initial development of pandemic influenza vaccines. A large investment in pandemic influenza vaccines in the last decade has resulted in much progress and a body of information that can now be applied to refine the established paradigm. Critical and complementary considerations for pandemic influenza vaccines include improved assessment of the pandemic potential of animal influenza viruses, proactive development and deployment of pandemic influenza vaccines, and application of novel platforms and strategies for vaccine production and administration.
Url:
DOI: 10.2217/fvl.15.69
PubMed: 26587050
PubMed Central: 4648374
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000815
Links to Exploration step
PMC:4648374Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Refining the approach to vaccines against influenza A viruses with pandemic potential</title><author><name sortKey="Czako, Rita" sort="Czako, Rita" uniqKey="Czako R" first="Rita" last="Czako">Rita Czako</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26587050</idno><idno type="pmc">4648374</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648374</idno><idno type="RBID">PMC:4648374</idno><idno type="doi">10.2217/fvl.15.69</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000815</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000815</idno><idno type="wicri:Area/Pmc/Curation">000815</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000815</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Refining the approach to vaccines against influenza A viruses with pandemic potential</title><author><name sortKey="Czako, Rita" sort="Czako, Rita" uniqKey="Czako R" first="Rita" last="Czako">Rita Czako</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD</wicri:regionArea></affiliation></author></analytic><series><title level="j">Future virology</title><idno type="ISSN">1746-0794</idno><idno type="eISSN">1746-0808</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Vaccination is the most effective strategy for prevention and control of influenza. Timely production and deployment of seasonal influenza vaccines is based on an understanding of the epidemiology of influenza and on global disease and virologic surveillance. Experience with seasonal influenza vaccines guided the initial development of pandemic influenza vaccines. A large investment in pandemic influenza vaccines in the last decade has resulted in much progress and a body of information that can now be applied to refine the established paradigm. Critical and complementary considerations for pandemic influenza vaccines include improved assessment of the pandemic potential of animal influenza viruses, proactive development and deployment of pandemic influenza vaccines, and application of novel platforms and strategies for vaccine production and administration.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101278124</journal-id><journal-id journal-id-type="pubmed-jr-id">34879</journal-id><journal-id journal-id-type="nlm-ta">Future Virol</journal-id><journal-id journal-id-type="iso-abbrev">Future Virol</journal-id><journal-title-group><journal-title>Future virology</journal-title></journal-title-group><issn pub-type="ppub">1746-0794</issn><issn pub-type="epub">1746-0808</issn></journal-meta><article-meta><article-id pub-id-type="pmid">26587050</article-id><article-id pub-id-type="pmc">4648374</article-id><article-id pub-id-type="doi">10.2217/fvl.15.69</article-id><article-id pub-id-type="manuscript">NIHMS724716</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Refining the approach to vaccines against influenza A viruses with pandemic potential</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Czako</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Subbarao</surname><given-names>Kanta</given-names></name><xref rid="FN1" ref-type="author-notes">*</xref><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD, USA</aff><author-notes><corresp id="FN1"><label>*</label>Author for correspondence: Tel.: +1 301 451 3839; Fax: +1 301 480 4749; <email>ksubbarao@niaid.nih.gov</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>25</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>11</month><year>2015</year></pub-date><volume>10</volume><issue>9</issue><fpage>1033</fpage><lpage>1047</lpage><pmc-comment>elocation-id from pubmed: 10.2217/fvl.15.69</pmc-comment>
<self-uri xlink:href="http://www.futuremedicine.com/doi/full/10.2217/fvl.15.69"></self-uri><abstract><p id="P1">Vaccination is the most effective strategy for prevention and control of influenza. Timely production and deployment of seasonal influenza vaccines is based on an understanding of the epidemiology of influenza and on global disease and virologic surveillance. Experience with seasonal influenza vaccines guided the initial development of pandemic influenza vaccines. A large investment in pandemic influenza vaccines in the last decade has resulted in much progress and a body of information that can now be applied to refine the established paradigm. Critical and complementary considerations for pandemic influenza vaccines include improved assessment of the pandemic potential of animal influenza viruses, proactive development and deployment of pandemic influenza vaccines, and application of novel platforms and strategies for vaccine production and administration.</p></abstract><kwd-group><kwd>antigenic mismatch</kwd><kwd>avian influenza</kwd><kwd>pandemic influenza</kwd><kwd>prepandemic vaccine</kwd><kwd>prime boost</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000815 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000815 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4648374
|texte= Refining the approach to vaccines against influenza A viruses with pandemic potential
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:26587050" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |